Cargando…
Tumor-related interleukins: old validated targets for new anti-cancer drug development
In-depth knowledge of cancer molecular and cellular mechanisms have revealed a strong regulation of cancer development and progression by the inflammation which orchestrates the tumor microenvironment. Immune cells, residents or recruited, in the inflammation milieu can have rather contrasting effec...
Autores principales: | Setrerrahmane, Sarra, Xu, Hanmei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5606116/ https://www.ncbi.nlm.nih.gov/pubmed/28927416 http://dx.doi.org/10.1186/s12943-017-0721-9 |
Ejemplares similares
-
Integrins as attractive targets for cancer therapeutics
por: Li, Meng, et al.
Publicado: (2021) -
Novel production method of innovative antiangiogenic and antitumor small peptides in Escherichia coli
por: Setrerrahmane, Sarra, et al.
Publicado: (2017) -
Trends in insulin resistance: insights into mechanisms and therapeutic strategy
por: Li, Mengwei, et al.
Publicado: (2022) -
Micropeptide MIAC inhibits the tumor progression by interacting with AQP2 and inhibiting EREG/EGFR signaling in renal cell carcinoma
por: Li, Mengwei, et al.
Publicado: (2022) -
Accurate control of dual-receptor-engineered T cell activity through a bifunctional anti-angiogenic peptide
por: Zhang, Erhao, et al.
Publicado: (2018)